Navigation Links
Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
Date:9/14/2010

nd vancomycin for intervening infections during the study.  The data indicated fidaxomicin was a superior therapy to vancomycin in preventing recurrence and in promoting global cure in patients requiring concomitant antibiotics.  The analysis from the Phase 3 trials indicated that in patients receiving concomitant antibiotics, those treated with fidaxomicin versus vancomycin had a significantly lower CDI recurrence rate (17% vs. 28%, p=0.039) and had a significantly improved global cure rate (73% vs. 60%, p=0.013).  At the same time, among subjects who received no concomitant antibiotics, recurrence in vancomycin-treated subjects was double that of fidaxomicin-treated subjects (23% vs. 11.5%, p<0.001).

Ellie J. Goldstein, M.D., from the R.M. Alden Research Laboratory in Santa Monica, CA, presented data on the antimicrobial susceptibilities of C. difficile isolates to fidaxomicin, vancomycin, metronidazole, and rifaximin cultured from fecal specimens collected from patients at study entry and at failure/recurrence in Optimer's second Phase 3 clinical trial. The data showed that there was no relationship between MICs of baseline CDI isolates and clinical outcome for fidaxomicin but there was a one dilution difference for vancomycin between cure and failure.  The MIC90s were generally low for fidaxomicin,  vancomycin, and metronidazole but the BI isolates generally had higher MICs for the four drugs tested than the BK, CF, DH, G, J, and Y group isolates. No resistance to either fidaxomicin or vancomycin developed during the 10-day treatment in this or in the first Phase 3 trial.  Rifaximin resistant strains, 8.1% of all strains, were isolated in both treatment groups with MIC90s higher in treatment failures than cures.

In an oral presentation, Dale N. Gerding, M.D., an investigator from the Hines VA Hospital in Chicago, IL, presented data on the C. difficile strain types isolated in Optimer's two fidaxomicin
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
2. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
3. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
4. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
5. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
6. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
7. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
8. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
9. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
10. Stemedica Announces Completion of Clinical Stem Cell Master Bank
11. DATATRAK International, Inc. Announces Initial Equity Research Coverage by Zacks Investment Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... October 20, 2014 , A ... disorders and the delivery of care has revealed changing ... worrying inequalities in the provision of healthcare services across ... commissioned by United European Gastroenterology (UEG), have been announced ... public awareness of the burden of GI disorders across ...
(Date:10/20/2014)... 20, 2014 OncLive® ... Cancer Center at Thomas Jefferson University has joined ... the Strategic Alliance Partnership program, the Sidney Kimmel ... to raise awareness of the Center’s cutting-edge research ... projects. Clinicians and other health care professionals from ...
(Date:10/19/2014)... The Latin American hardware encryption display ... America with analysis and forecast of revenue. This market ... expected to reach $2,366.8 million by 2018, at a ... through the TOC of the Latin American hardware encryption ... analysis provided. It also provides a glimpse of the ...
(Date:10/19/2014)... 19, 2014 The Asia-Pacific Bromine ... in Asia-Pacific with analysis and forecast of revenue. ... Pacific Bromine Market report, to get an idea ... a glimpse of the segmentation in the Asia-Pacific ... and figures. , http://www.micromarketmonitor.com/market/asia-pacific-bromine-6741503144.html , ...
Breaking Biology Technology:Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 3
... Sept. 16 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc.,(TSX:SBS), a ... metabolic and cardiovascular diseases, today announced that it,is ... human clinical trial of,plant-produced insulin now that the ... application has passed. SemBioSys submitted,the application in July ...
... of a Phase ... of Seasonal Influenza Vaccine, ROCKVILLE, Md., Sept. 16 ... volunteers in a Phase,II clinical trial of its virus-like particle ... clinical trial will,evaluate the safety and immunogenicity of different doses ...
... Inc. (the,"Company" or "MIGENIX") (TSX: MGI; OTC: ... diseases, reports financial results for the three,months ... corporate update on its programs,and other matters., ... Omiganan 1% gel (Omigard(TM)/CPI-226/MX-226; topical cationic peptide;,prevention ...
Cached Biology Technology:SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND 2SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND 3Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate 2Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate 3Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate 4Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate 5MIGENIX Reports First Quarter Fiscal 2009 Financial Results 2MIGENIX Reports First Quarter Fiscal 2009 Financial Results 3MIGENIX Reports First Quarter Fiscal 2009 Financial Results 4MIGENIX Reports First Quarter Fiscal 2009 Financial Results 5MIGENIX Reports First Quarter Fiscal 2009 Financial Results 6MIGENIX Reports First Quarter Fiscal 2009 Financial Results 7MIGENIX Reports First Quarter Fiscal 2009 Financial Results 8MIGENIX Reports First Quarter Fiscal 2009 Financial Results 9MIGENIX Reports First Quarter Fiscal 2009 Financial Results 10MIGENIX Reports First Quarter Fiscal 2009 Financial Results 11
(Date:10/14/2014)... 2014)—It,s been millions of years since T. rex ... by Ohio University scientists is breathing life back into ... dinosaur snouts. The research has important implications for how ... to enhance the sense of smell and cool their ... Ohio University doctoral student Jason Bourke, lead author of ...
(Date:10/14/2014)... is how to produce enough food to feed the ... Agriculture Organization of the United Nations predicts that food ... to feed a growing global population, and plants are ... production. Plants—grains, cereals, fruits, vegetables, and more—feed humans ... must tap into our knowledge of how plants work ...
(Date:10/14/2014)... fish oil supplements, rich in omega-3 fatty acids, do not ... which the heart can beat as fast as 150 beats ... the Montreal Heart Institute were published in the Journal ... , For the trial, 337 patients with atrial fibrillation not ... of fish oil a day or to placebo for up ...
Breaking Biology News(10 mins):Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3
... , , SEATTLE, Dec. 18 Pacific ... a leading provider of specialized central laboratory and contract research ... that were voted upon at the Company,s Annual Meeting on ... approve a change in the Company,s name to "Pacific Biomarkers, ...
... PITTSBURGHResearchers at Carnegie Mellon University,s National Robotics Engineering ... computer vision and machine learning to inspect and grade ... quality tasks that until now could only be ... fall, the machine classified and sorted harvested plants more ...
... 17, 2009 Time and time again, it has been ... risks associated with the comorbidities of obesity. With only ... Institutes of Health exercise guidelines of 300 minutes/week, a study ... Nutrition Education and Behavior explores the paradox that exists ...
Cached Biology News:Pacific Biometrics, Inc. Stockholders Approve Company Name Change to Pacific Biomarkers, Inc. 2Pacific Biometrics, Inc. Stockholders Approve Company Name Change to Pacific Biomarkers, Inc. 3Pacific Biometrics, Inc. Stockholders Approve Company Name Change to Pacific Biomarkers, Inc. 4Carnegie Mellon engineers develop machine that visually inspects and sorts strawberry plants 2Negative emotions outweigh intent to exercise at health clubs 2
Syd-2 (cL-19)...
... isolation and affinity purification of small ... Hydrophobic, monodisperse magnetic particles (2.8 m ... further surface activation is not required. ... optimal orientation for affinity purification of ...
ZO-2 (H-110)...
p-Bcl-2 (Thr 74)...
Biology Products: